Logo

Bioscientia Joins Siemens/Sequenom Partnership to Evaluate MassArray for Clinical Dx

Jun 09, 2005

NEW YORK, June 9 (GenomeWeb News) - Bioscientia, a reference laboratory based in Germany, will join Siemens Medical Solutions and Sequenom to evaluate Sequenom's MassArray platform for molecular diagnostic applications, Sequenom said today.

 

Under the agreement, Sequenom will provide its MassArray Compact platform, consumables, technical support, and assays for specific conditions, including deep vein thrombosis and HIV. With funding and engineering expertise from Siemens, Bioscientia will test the platform in a benchmarking study.

 

Bioscientia, based in Ingelheim, is the second reference lab after Specialty Laboratories in April to join Siemens' and Sequenom's "working group," which the companies founded in late 2004. The first phase of the progam, which will eventually include four laboratories, will be a benchmarking study, to be completed this year, to evaluate the analytical data quality and workflow of the MassArray system.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.